Evolus Reports Q3 2026 Revenue Growth Driven by Toxins and Fillers
Evolus (EOLS) reported third-quarter revenue of $78 million, a 13% increase year-over-year. The growth was fueled by an 11% rise in toxin revenue to $70.1 million and a significant 40% surge in HA gel revenue, which reached $7.9 million due to the expansion of the Evolysse and Estyme portfolios. The company achieved its fourth consecutive quarter of positive adjusted EBITDA, totaling $1.2 million, aided by disciplined expense management. While reporting a GAAP operating loss of $8.4 million, this represents an improvement over the previous year's loss. Management also updated full-year revenue guidance to a range of $330 million to $337 million. Looking ahead, Evolus is preparing for several regulatory milestones, including anticipated FDA approval for Evolysse Sculpt in Q4 2026 and an upcoming submission for Evolysse Lips. The company also noted it has secured 12 months of Jeuveau safety stock in the U.S. to mitigate potential pharmaceutical tariff risks.
Tickers: $EOLS
Topics: EBITDA Financial Guidance Revenue Growth Toxins and Fillers